Article
Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Cancer letters - 28 Mar 2016
Amoury Manal, Kolberg Katharina, Pham Anh-Tuan, Hristodorov Dmitrij, Mladenov Radoslav, Di Fiore Stefano, Helfrich Wijnand, Kiessling Fabian, Fischer Rainer, Pardo Alessa, Thepen Theophilus, Hussain Ahmad F, Nachreiner Thomas, Barth Stefan
Abstract excerpt
Triple-negative breast cancer (TNBC) is associated with poor prognosis and high prevalence among young premenopausal women. Unlike in other breast cancer subtypes, no targeted therapy is currently available. Overexpression of epithelial cell adhesion molecule (EpCAM) in 60% of TNBC tumors correlates with poorer prognosis and is associated with cancer stem cell phenotype. Thus, selective elimination of EpCAM(+)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.